Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9
Zogenix, a biopharmaceutical company, announced a change in the date for its earnings release and conference call to November 9, 2020, at 4:30 PM ET. The company will report financial results for the three and nine months ended September 30, 2020. Zogenix is focused on developing therapies for rare diseases, with its leading product, FINTEPLA, approved for treating seizures associated with Dravet syndrome. The company has ongoing development programs for additional treatments for rare childhood-onset epilepsies and genetic disorders.
- Zogenix's therapy FINTEPLA has FDA approval for Dravet syndrome.
- The company has two late-stage development programs for rare diseases.
- None.
EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call. The Company will now report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Monday, November 9, 2020, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Monday, November 9, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 877-407-9716 |
| International: | 201-493-6779 |
| Conference ID: | 13711927 |
| Webcast: | http://public.viavid.com/index.php?id=141969 |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
In Europe: Kerry Lloyd-Jones, Account Director, Porter Novelli
+44 (0) 7949 794 290 | kerry.lloyd-jones@porternovelli.co.uk
In the US: Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
When will Zogenix report its earnings for Q3 2020?
What time is Zogenix's conference call for earnings?
What therapies is Zogenix currently developing?
